-
-
-
-
-
-
-
ResMed (RMD) PT Lowered to $260 at Stifel
-
-
-
-
-
-
-
ResMed (RMD) PT Raised to $304 at Morgan Stanley
-
-
-
-
-
-
-
ResMed (RMD) PT Raised at KeyBanc; 'Carrying GM Momentum into FY26'
-
-
-
-
-
-
-
RBC Capital Upgrades ResMed (RMD) to Outperform
-
-
-
-
-
-
-
ResMed (RMD) PT Lowered to $248 at Piper Sandler Following 'Mixed FQ3 Print'
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) and ResMed (RMD) Added to Goldman APAC Director's Cut Conviction List
-
-
-
-
-
-
-
ResMed (RMD) Tops Q2 EPS by 11c
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

